HR and breast neoplasm: Together, the TMAs included 834 total breast tumor cores from 278 unique patients, including HER2+ (regardless of HR status; n = 158, 57%), HR+/HER2− (n = 31, 11%) and HR−/HER2− (TNBC; n = 89, 32%) (Tables 3, 5).